Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

Company Overview - Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways [3] - The lead drug candidate, denifanstat, is an oral, once-daily selective FASN inhibitor aimed at treating metabolic dysfunction associated steatohepatitis (MASH) [3] - Denifanstat has received Breakthrough Therapy designation from the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis [3] Clinical Development - The Phase 2b clinical trial, FASCINATE-2, of denifanstat in MASH has been successfully completed with positive results [3] - End-of-Phase 2 interactions with the FDA have been completed, supporting the advancement of denifanstat into Phase 3 development [3] Upcoming Presentation - An oral presentation on FASN inhibitors will be held at the 9th Annual MASH-TAG Conference from January 9-11, 2025, in Park City, Utah [1] - The presentation will be led by Marie O' Farrell, Ph.D., Senior Vice President of Research and Development at Sagimet, focusing on the differentiated mechanism of action of denifanstat and its anti-fibrotic effects observed in the FASCINATE-2 study [2][1]